Axogen, Inc. (AXGN) stock
Close on Nov 12, 2026Market cap $3.31BP/E –Yield –
Axogen, Inc. grew revenue 24.3% to $266.93M over the twelve months to Sep 30, 2026. Operating income fell 450.4% to -$13.81M, moving the operating margin from 1.8% to -5.2%. Free cash flow was $22.04M, up 559.7% from a year earlier. At the latest close the market valued the company at $3.31B.
Key statistics
Valuation at the latest close; fundamentals over the trailing twelve months, balances at Sep 30, 2026
Valuation
- Market cap
- $3.31B
- P/E ratio
- –
- Price to sales
- 12.40
- Price to book
- 6.67
- Dividend yield
- –
- Free cash flow yield
- 0.67%
Fundamentals
- Revenue
- $266.93M
- Net income
- -$31.92M
- EPS, diluted
- -$0.65
- Free cash flow
- $22.04M
- Book value per share
- $8.06
- Diluted shares
- 62M
Trading
- Next earnings
- Feb 23, 2027 (estimated, before the open)
- Previous close
- $58.63
- Open
- $57.75
- Day's range
- $53.87 – $58.35
- Volume
- 3,055,457
- Average volume (20 days)
- 2,090,325
- Index membership
- Russell 2000, Russell 3000
- Beta (5 years)
- 1.15
- 52-week range
- $23.00 – $59.72
- RSI (14 days)
- 69.3
- Volatility (1 year)
- 61.2%
- Relative volume
- 2.17×
- WACC
- 10.6%
On 2 of our idea lists: Institutions accumulating, New highs on volume
Index membership is inferred from the holdings of funds that track each index (IWM, IWV), as reported to the SEC for Jun 30, 2026. Join dates come from quarterly fund reports since 2019, so they are accurate to the quarter.
Market cap history
Month-end market cap since 2011, using shares outstanding reported at the time
Total return vs. the S&P 500
Price change plus reinvested dividends, to the close on Nov 12, 2026. The S&P 500 is measured by the SPY fund.
| Period | AXGN | S&P 500 | Difference | AXGN per year | S&P 500 per year |
|---|---|---|---|---|---|
| 1 month | +49.3% | -2.7% | +52.0 pts | ||
| 3 months | +11.5% | -1.7% | +13.3 pts | ||
| Year to date | +69.3% | +11.9% | +57.4 pts | ||
| 1 year | +130.0% | +12.0% | +118.0 pts | ||
| 3 years | +1003.6% | +78.2% | +925.4 pts | +122.6% | +21.2% |
| 5 years | +355.2% | +73.2% | +282.0 pts | +35.4% | +11.6% |
| 10 years | +548.0% | +309.6% | +238.3 pts | +20.5% | +15.1% |
Fifteen years at a glance
Fiscal years 2011 to 2025 and trailing twelve months, USD
Revenue
Gross profit
Operating income
Net income
EPS, diluted
Free cash flow
Press releases
Releases Axogen filed with the SEC as exhibits to Form 8-K or 6-K
- Update
- Results
- Results
- Results
- Update
- Update
About Axogen
Electromedical & Electrotherapeutic Apparatus
Axogen develops and commercializes regenerative medicine technologies designed to repair and regenerate peripheral nerves. Its product portfolio features processed human nerve allografts, including Avance, as well as extracellular matrix devices such as Axoguard nerve connectors, protectors, and caps. It also offers Avive+ soft tissue matrix for surgical wound healing. The company organizes its business across four primary clinical application areas: extremities, oral maxillofacial and head and neck, breast reconstruction neurotization, and urology. Its solutions are utilized by surgeons and healthcare providers treating patients with traumatic nerve damage or surgical nerve transections.
Company profile, executives and historyAxogen stock: common questions
What is Axogen's stock price?
AXGN closed at $55.40 on Nov 12, 2026, down 5.51% on the day. Over the past 52 weeks it traded between $23.00 and $59.72.
What is Axogen's market cap?
Axogen was worth $3.31B at the close on Nov 12, 2026: the share price times the diluted shares outstanding.
What is AXGN's P/E ratio?
Axogen lost money over the twelve months to Sep 30, 2026 (diluted EPS -$0.65), so it has no meaningful P/E ratio.
How much revenue does Axogen make?
Axogen reported revenue of $266.93M for the twelve months to Sep 30, 2026, up 24.3% from a year earlier.
Does Axogen pay a dividend?
No. Axogen has not paid a cash dividend over the last twelve months.
When does Axogen report earnings next?
Axogen is expected to report Q4 FY2026 results on Feb 23, 2027, before the open. The date is estimated from its past reporting pattern until the company confirms it.
How has AXGN stock performed over the past year?
Including dividends, AXGN returned +130.0% over the past year, against +12.0% for the S&P 500.
How many AXGN shares are sold short?
7M shares were sold short at the latest FINRA report, 12.67% of the float, or 3.3 days of average trading volume.
Who are Axogen's competitors?
Companies most similar to Axogen by business, industry and size include MDXG, INMD, LMAT, ANGO, BVS.
See a number that looks wrong?